319 related articles for article (PubMed ID: 18509855)
1. Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Arai A; Tomiyama M; Kannari K; Kimura T; Suzuki C; Watanabe M; Kawarabayashi T; Shen H; Shoji M
Synapse; 2008 Aug; 62(8):632-5. PubMed ID: 18509855
[TBL] [Abstract][Full Text] [Related]
2. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
3. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
[TBL] [Abstract][Full Text] [Related]
4. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
5. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
[TBL] [Abstract][Full Text] [Related]
7. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
8. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
9. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
10. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
11. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Chotibut T; Fields V; Salvatore MF
Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
13. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Maeda T; Nagata K; Yoshida Y
Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
[TBL] [Abstract][Full Text] [Related]
14. Chronic intermittent L-DOPA treatment induces changes in dopamine release.
Lundblad M; af Bjerkén S; Cenci MA; Pomerleau F; Gerhardt GA; Strömberg I
J Neurochem; 2009 Feb; 108(4):998-1008. PubMed ID: 19196428
[TBL] [Abstract][Full Text] [Related]
15. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Ferrario JE; Rojas-Mayorquín AE; Saldaña-Ortega M; Salum C; Gomes MZ; Hunot S; Raisman-Vozari R
J Neurochem; 2008 Oct; 107(2):443-52. PubMed ID: 18752647
[TBL] [Abstract][Full Text] [Related]
16. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Ferger B
Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
[TBL] [Abstract][Full Text] [Related]
18. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Chotibut T; Apple DM; Jefferis R; Salvatore MF
PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
[TBL] [Abstract][Full Text] [Related]
19. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
[TBL] [Abstract][Full Text] [Related]
20. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Enna SJ; Reisman SA; Stanford JA
Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
